Intensity Therapeutics (INTS) Assets Average (2023 - 2026)

Intensity Therapeutics (INTS) has 4 years of Assets Average data on file, last reported at $13.2 million in Q1 2026.

• Quarterly Assets Average rose 236.29% year-over-year to $13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.2 million (up 236.29% YoY) and the FY2025 annual result came in at $9.4 million, down 14.47% from the prior year.
• Assets Average rose to $13.2 million in Q1 2026, from $11.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $17.5 million in Q3 2023 to a low of $3.8 million in Q2 2025.
• A 4-year average of $10.1 million and a median of $10.5 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2025 — Assets Average sank 73.58% — and 2026, when it jumped 236.29%.
• Tracing INTS's Assets Average over 4 years: stood at $17.1 million in 2023, then slumped by 70.7% to $5.0 million in 2024, then surged by 136.95% to $11.8 million in 2025, then gained by 11.42% to $13.2 million in 2026.
• The last three Assets Average figures came in at $13.2 million (Q1 2026), $11.8 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.